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Abstract
Background
In 2012, an Indian parliamentary committee reported that manufacturing licenses for large
numbers of fixed dose combination (FDC) drugs had been issued by state authorities with-
out prior approval of the Central Drugs Standard Control Organization (CDSCO) in violation
of rules, and considered that some ambiguity until 1 May 2002 about states’ powers might
have contributed. To our knowledge, no systematic enquiry has been undertaken to deter-
mine if evidence existed to support these findings. We investigated CDSCO approvals for
and availability of oral FDC drugs in four therapeutic areas: analgesia (non-steroidal anti-in-
flammatory drugs [NSAIDs]), diabetes (metformin), depression/anxiety (anti-depressants/
benzodiazepines), and psychosis (anti-psychotics).
Methods and Findings
This was an ecologic study with a time-trend analysis of FDC sales volumes (2007–2012)
and a cross-sectional examination of 2011–2012 data to establish the numbers of formula-
tions on the market with and without a record of CDSCO approval (“approved” and “unap-
proved”), their branded products, and sales volumes. Data from the CDSCO on approved
FDC formulations were compared with sales data from PharmaTrac, a database of national
drug sales. We determined the proportions of FDC sales volumes (2011–2012) arising from
centrally approved and unapproved formulations and from formulations including drugs
banned/restricted internationally. We also determined the proportions of centrally approved
and unapproved formulations marketed before and after 1 May 2002, when amendments
were made to the drug rules. FDC approvals in India, the United Kingdom (UK), and United
States of America (US) were compared.
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For NSAID FDCs, 124 formulations were marketed, of which 34 (27%) were centrally ap-
proved and 90 (73%) were unapproved; metformin: 25 formulations, 20 (80%) approved,
five (20%) unapproved; anti-depressants/benzodiazepines: 16 formulations, three (19%)
approved, 13 (81%) unapproved; anti-psychotics: ten formulations, three (30%) approved,
seven (70%) unapproved. After 1 May 2002, the proportions of approved FDC formulations
increased for NSAIDs (26%/28%) and anti-psychotics (0%/38%) and decreased for metfor-
min (100%/75%) and anti-depressants/benzodiazepines (20%/18%), and the overall pro-
portion approved remained similar before and after that date.
FDC formulations gave rise to multiple branded products, ranging from 211 anti-psychot-
ic FDC products from ten formulations to 2,739 NSAID FDC products from 124 formulations.
The proportions of FDC sales volumes arising from unapproved formulations were as fol-
lows: anti-depressants/benzodiazepines, 69%; anti-psychotics, 43%; NSAIDs, 28%; and
metformin, 0.4%. Formulations including drugs banned/restricted internationally comprised
over 12% of NSAID FDC sales and 53% of anti-psychotic FDC sales. Across the four thera-
peutic areas, 14 FDC formulations were approved in the UK and 22 in the US.
Conclusions
There was evidence supporting concerns about FDCs. Metformin excepted, substantial
numbers of centrally unapproved formulations for NSAID, anti-depressant/benzodiazepine,
and anti-psychotic FDCs were marketed; sales volumes were high. The legal need for cen-
tral approval of new drugs before manufacture has been in place continuously since 1961,
including for FDCs meeting the applicable legal test. Proportions of centrally unapproved
formulations after 1 May 2002 did not decrease overall, and no ambiguity was found about
states’ licensing powers. Unapproved formulations should be banned immediately, prioritis-
ing those withdrawn/banned internationally and undertaking a review of benefits and risks
for patients in ceasing or switching to other medicines. Drug laws need to be amended to
ensure the safety and effectiveness of medicines marketed in India.
Introduction
Drug regulators internationally have expressed concerns about the quality of medicines manu-
factured in India [1–3]. Nationally, the rigour of the national regulator, the Central Drugs Stan-
dard Control Organization (CDSCO), based in the Ministry of Health and Family Welfare, in
safeguarding the interests of patients has been questioned in parliamentary and academic re-
ports [4–7]. Particular concerns have been approvals for and the proliferation of fixed dose
combination (FDC) products, formulations comprised of two or more drugs combined in a
fixed ratio of doses and available in a single dosage form [5,6,8]. Thousands of FDCs are avail-
able in India [9]. Many are judged safe and effective and are widely used in situations where
both the drug combination and the doses needed are standardised and stable, for example,
FDCs for the treatment of human immunodeficiency virus (HIV) or tuberculosis infections,
and for contraception. Many others have been judged unsafe, even dangerous, in terms of the
combinations of drugs, for example, FDCs comprising multiple drugs from the same therapeu-
tic group (chlorpromazine + trifluoperazine, dual phenothiazine anti-psychotics; mefenamic
acid + ibuprofen, dual non-steroidal anti-inflammatory drugs [NSAIDs]) and combinations of
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centrally acting drugs (chlordiazepoxide + trifluoperazine) [10–12]. In the former, risks of ad-
verse effects are compounded (including central nervous system [CNS] toxicity and cardiac ar-
rhythmia [phenothiazine] and upper gastrointestinal complications [NSAIDs]). In the latter,
while both drugs may be indicated, separate dose adjustments cannot be easily undertaken.
In 2007, the CDSCO banned from sale some 294 FDCs because they had never been ap-
proved by the central regulator but had been granted manufacturing/distribution licenses by
state drug authorities; the list was published in 2014 [13,14]. FDC manufacturers disputed the
ban and obtained a stay from the Madras High Court [13]. The matter remains unresolved.
Concerns about regulatory capacity and rigour led to an examination in 2011 of the CDSCO
by the Department-Related Parliamentary Standing Committee on Health and Family Welfare,
one of over 20 standing committees consisting of members of Parliament and established by
the Parliament of India to undertake specialist parliamentary work [6]. In 2012, it issued its re-
port (the 59th Report) [6]. This report highlighted multiple deficiencies in the approval pro-
cesses of the CDSCO, noting that these were compounded by understaffing, a lack of
appropriate skills, and inadequate infrastructure. In respect of FDCs, the committee reported
that the issue of manufacturing licenses being granted by some states for FDCs without prior
CDSCO approval had been “first deliberated” by the Drugs Technical Advisory Board in 2000,
and the committee expressed concern that “even after a lapse of a decade, no serious action has
been taken”, and stated the following:
Unfortunately some State Drug Authorities have issued manufacturing licenses for a very
large number of FDCs without prior clearance from CDSCO. This is in violation of rules
though till May 2002, there was some ambiguity on powers of the State Drug Authorities in
this respect. However the end result is that many FDCs in the market have not been tested
for efficacy and safety. This can put patients at risk. (Section 9 of [6])
The committee also noted that multiple FDCs available in India had been rejected by regula-
tors in Europe, North America, and Australia, while others never had approval applications
submitted outside India (Section 7 of [6]). The report, however, provided no systematic exami-
nation of regulatory or drug utilisation data to support its complaints.
Concern with FDCs
To our knowledge, this is the first empiric study into the concerns described about FDCs by
the 59th Report. It examines the regulation and use in India of oral FDCs in four therapeutic
areas: analgesia (NSAIDs), diabetes (metformin), anxiety/depression (benzodiazepines/anti-
depressants), and psychosis (anti-psychotics). We chose these areas because the drugs are com-
monly used and/or are associated with considerable potential for interactions and adverse
events. Examples of both NSAID and anti-psychotic FDCs were highlighted in the 59th
Report.
India’s FDC Regulatory Framework
The much-amended Drugs and Cosmetics Act, 1940, and Drugs and Cosmetics Rules, 1945,
govern the regulation of drugs [15] (S1 and S2 Texts). The 1940 law, passed under British colo-
nial rule, placed responsibility for imports on central government, with the states being respon-
sible for manufacture, distribution, and sale. Following independence in 1947 and subsequent
adoption of the Constitution, “drugs” became a matter contained in the “Concurrent List” so
that both the national Parliament and the state legislatures had, and have, power to make laws
in relation to them. In 1952, national rules introduced the concept of a “new drug” along with
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the requirement for prior central approval for import (S3 Text). This was followed in 1961 by
the requirement for prior central approval for manufacture, along with an obligation on state
license applicants to produce evidence that the drug had been approved (S4 and S5 Texts).
FDCs were not specifically mentioned, but they were regarded as new drugs, with recorded
central approvals for FDC formulations dating (continuously) from 1961.
Increased central control of drug regulation has occurred incrementally ever since, whilst
the states have retained their licensing powers over the manufacturing and sale of most drugs.
A 1988 amendment inserted a new Part XA into the national rules entitled “Import or manu-
facture of new drugs for clinical trials or marketing” (S6 Text). Part XA included (and includes)
requirements for pre-manufacturing central approval before a state manufacturing license is
granted and for license applicants to produce evidence of that approval, whilst expressly in-
cluding FDCs in the definition of a new drug and setting out specific data submission require-
ments for FDCs. After September 1988, FDCs combining drugs for the first time that had been
individually approved previously, or previously combined FDCs with new claims, were ex-
pressly included within the definition of a “new drug” under Rule 122E(c). Those FDCs there-
fore required central approval prior to manufacturing under Rules 122B or 122C, and
applicants had to submit evidence to state authorities of that prior approval. This is reflected in
the heading of Rule 122D: “Application for permission to import or manufacture fixed dose
combination of drugs”.
In 2001, the rules were amended again to impose the legal duty on the CDSCO to be satis-
fied when approving new drugs for import or manufacture that they are safe and effective. The
duty was imposed for FDCs as well, with the amendment further stating that FDCs needed
prior approval even though they fell within the definition of new drugs and so were covered as
far as the “safe and effective duty” was concerned, whilst the post-1961 provisions and the 1988
amendments covered them as far as the requirement for prior central approval was concerned.
An amendment in May 2002, inserting Rules 69(6) and 75(6), essentially duplicated the re-
quirement to produce evidence of prior approval of “new drugs” that had been in the rules
since 1961, and extended it to require evidence of approval in favour of the applicant. The 59th
Report (Section 9.2 of [6]) noted “some ambiguity” until May 2002. We identified no ambigui-
ty in the rules. Our detailed analysis of the rules (S1 Text) leads us to consider that an FDC
needed prior central approval for manufacture—and the submission to states of evidence of
that approval—from 1961 if it fell within the three different definitions of a “new drug” apply-
ing from 1961–1988, 1988–1999, and 1999 onwards (see Box 1). Rules 69(6) and 75(6) are not
relevant to determining that question, but they imposed an additional requirement of produc-
ing evidence of approval in favour of the applicant.
Further amendments in 2005 removed references to minimum numbers or ranges of partic-
ipants and sites in “new drug” clinical trials and gave the CDSCO discretion to override data
submission rules. For 4 y after approval, or after inclusion in the Indian Pharmacopoeia if earli-
er, companies wanting to market new drugs—including FDCs—must obtain approval of their
own formulation from the CDSCO. After 4 y, new drugs cease to be deemed “new” drugs, and
applications for manufacturing/distribution licences can be made to state licensing authorities
without prior CDSCO approval.
Objectives of This Study
We aimed to determine if evidence existed to support the concerns of the 59th Report. Our ob-
jectives were to (i) determine the numbers of approvals granted by the CDSCO (1961–2013)
for oral FDC formulations in the four therapeutic areas of interest; (ii) determine for each ther-
apeutic area the numbers of FDC formulations on the market (2011–2012), their CDSCO
An Examination of FDCs in Four Therapeutic Areas
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Box 1. Chronology and Detail of Requirements for Central Approval
for Import and Manufacture of Fixed Dose Combinations
1961–1988
(1) Prior central approval for manufacture was required for an FDC after June 1961,
until September 1988, if either:
a the composition of the FDC in question was not at the time generally recognised
among experts as safe for use under the conditions recommended or suggested in the
label; or
b the composition of the FDC, as a result of investigations for determining its safety for
use under such conditions, was so recognised, but it had not, otherwise than during
the course of such investigations, been used to any large extent or for any appreciable
length of time under those conditions,
and those applying to a state for a licence to manufacture an FDC or its preparations
which fell within (a) or (b) were required to produce along with their application evi-
dence that the drug had already been centrally approved.
1988–1999
(2) Between September 1988 and August 1999, prior central approval for import and
manufacture of an FDC was legally required if:
a the drugs being combined (i) had been individually approved earlier for certain claims,
and (ii) it is proposed to combine them for the first time in a fixed ratio; or
b the drugs being combined (i) had been individually approved earlier for certain claims,
and (ii) it is proposed to change the ratio, indications, dosage, dosage form, or route of
administration; or
c of the drugs being combined (i) one or more of them had not been previously ap-
proved, and (ii) (at least) the combination (and, possibly, each of the individually un-
approved drugs) constituted a new substance of chemical, biological, or
biotechnological origin in bulk or prepared dosage form used for prevention, diagno-
sis, or treatment of disease in man or animal; which, except during local clinical trials,
has not been used in the country to any significant extent; and which, except during
local clinical trials, has not been recognised in the country as effective and safe for the
proposed claims,
and those applying to a state had to produce evidence that the drug had already been cen-
trally approved. The requirement in effect lapsed after 4 y from either the date of the first
approval or, if earlier, from the date of the inclusion of the FDC in the Indian
Pharmacopoeia.
Since August 1999
(3) Since August 1999, the position has been the same as under (2) above, but the criteria
in (c)(ii) have changed, so that since August 1999 (c) would read:
of the drugs being combined (i) one or more of them has not been previously approved,
and (ii) (at least) the combination (and, possibly, each of the individually unapproved
drugs) constitutes a drug within the definition of the Act (see S1 Text) including drug
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approval status, the numbers of branded products marketed, and the relative contributions to
FDC sales (2011–2012) of formulations with and without a record of CDSCO approval (“ap-
proved” and “unapproved”); and (iii) evaluate the impact of the May 2002 amendment to the
rules by determining the proportions of new formulations launched on the market before and
after 1 May 2002 that had CDSCO approval, the numbers of products arising, and their sales
volumes (2011–2012).
Finally, we wished to determine if FDC formulations available in India were approved by
United Kingdom (UK) and/or United States of America (US) regulators or included drugs
banned, restricted, or unapproved internationally, and to apply our findings to make recom-
mendations for rationalising the regulation of, and hence the use of, FDCs in India.
Methods
This was an ecologic study of FDC approvals in India. It included a time-trend analysis of FDC
sales volumes (2007–2012) in each of the four therapeutic areas of study, with a cross-sectional
examination of the 2011–2012 data to determine the contributions to FDC product numbers
and sales volumes of CDSCO-approved and-unapproved formulations.
FDC Approvals in India
Using publicly accessible records available from the CDSCO for the period 1961–2013, we col-
lated information on FDC approvals granted annually in each area [16]. The CDSCO listed ap-
provals chronologically in a portable document format (pdf) that included the drugs
comprising individual FDC formulations, indication, and the date of approval. Relevant infor-
mation was extracted into an Excel spreadsheet. We focussed on original formulation approval,
that is, the first approval granted for the drug combination in the FDC being examined. We
categorised a formulation as “approved” if the combination of drugs, irrespective of dose
amounts or modified release variations, was ever recorded as approved by the CDSCO. We cat-
egorised a formulation as “unapproved” if it was not included in the list of CDSCO approvals,
1961–2013 (Box 2). We assumed the CDSCO approval records were complete. No information
was available publicly on the clinical evidence that was provided to support approvals. State
drug authority records of FDC manufacturing/distribution/sale licences were unavailable, but
from the list of 294 FDCs banned by the CDSCO in 2007, we identified FDCs in the study cate-
gories that had state licenses only [14].
FDC Approvals in the UK and US
To determine approvals in the UK and US, we searched the Medicines and Healthcare Prod-
ucts Regulatory Agency (MHRA) and Food and Drug Administration (FDA) approval listings
for 2014 [17,18]. The FDA index (the Orange Book) lists all approved FDCs and single drug
formulations (SDFs) alphabetically by generic name [18]. The MHRA publishes no index of
bulk substance—if it has not been used significantly in India (and if there has been any
limited use, such use must have been with the permission of the central licensing au-
thority) under the conditions prescribed, recommended, or suggested in its label, and
has not been recognised by the central authority as effective and safe for the proposed
claims (S7 Text).
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generic name FDC approvals, and its list of approvals does not include medicines licensed cen-
trally by the European Medicines Agency [17], so to minimise the risk of overlooking FDCs ap-
proved for use in the UK, we also examined listings in the British National Formulary and in
the Monthly Index of Medical Specialties (MIMS) [12,19].
FDC Sales in India
We determined for each therapeutic area the numbers of FDC formulations and branded prod-
ucts marketed, and we undertook a time-trend analysis of annual sales volumes over 5 y, 2007–
Box 2. Glossary
“Approved”
This single term is used in the paper to encompass the prior action required by the
CDSCO before a state licensing authority can give a license for manufacture/sale/distri-
bution of a new drug. In the Indian legal documents, the terms used are as follows: the
CDSCO gives “permission” for import of new drugs, must “approve”manufacture of
new drugs, and gives “permission” for the import and manufacture of new drugs, includ-
ing FDCs.
“Unapproved”
This term is used in the paper to encompass FDC formulations for which we found no
record of CDSCO approval. We assumed CDSCO records were complete.
Drug
A clinically active component in a formulation.
Drugs Technical Advisory Board
The board established under Section 5 of the Drugs and Cosmetics Act, 1940, to advise
the central and state governments on technical matters arising out of the administration
of the act.
Formulation
The drugs combined together to make an FDC product.
Product
The finished FDC as manufactured and named (or branded) by a pharmaceutical com-
pany. Multiple companies may choose to manufacture FDCs of the same formulation.
FDCs made by different pharmaceutical companies are given brand names to distinguish
them from FDCs of the same formulation made by other companies.
State licensing authority
The state-based authority responsible for manufacture, distribution, and sale of drugs;
drugs are required to have a state license before they are marketed.
An Examination of FDCs in Four Therapeutic Areas
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2012. Data were obtained from PharmaTrac, a commercial database comprising monthly au-
dits of pharmaceutical product sales through multiple supply routes (some 5,000 pharmaceuti-
cal companies, 18,000 distributers and stockists, and 32,000 sub-stockists) to over 500,000
retailers, hospitals, and dispensing doctors in 23 regions of India [20]. The audits capture 35%
of national sales. The sampling data are projected to estimate national sales totals. The data
largely represent private prescription sales; 85% are based on retailer sales, and 15% on drugs
supplied through hospitals and dispensing doctors. They include generic and branded product
names, manufacturers, sales volumes and value, and date of market launch. Each formulation
has a code that identifies it in the database according to therapy type and treatment group, so,
for example, diclofenac + paracetamol is M1A14, a musculoskeletal therapy in the anti-rheu-
matic systemic non-steroidal group; metformin + gliclazide is A10B10, an alimentary tract and
metabolism therapy in the oral anti-diabetic group. Sales volumes are reported as the numbers
of units of ten tablet/capsule doses; we converted units to the numbers of tablets/capsules.
Value is reported in rupees; we used current exchange rates to report in US dollars. We exam-
ined monthly data available for the 5-y period November 2007–October 2012. We adhered to
SAMPL guidelines for reporting [21].
There was a large amount of data; in presenting the results, we focus on the most recent
12-mo period, November 2011–October 2012. For each therapeutic area, we categorised sales
according to whether FDC formulations had a record of approval by the CDSCO. Taking into
account the 59th Report note on “ambiguity” in the national rules (Section 9.2 of [6]) until 1
May 2002 regarding the powers of state drug authorities to grant manufacturing licenses for
FDC formulations that did not have prior CDSCO approval, we also examined CDSCO ap-
provals for FDC formulations marketed before and after 1 May 2002, anticipating that all new
formulations marketed after 1 May 2002 would have CDSCO approval. (S1 Table includes the
individual formulation and product data for each of the 5 y examined.)
Data extraction. We searched the PharmaTrac database according to therapy and treat-
ment group in the first instance. For each therapeutic area, we identified the FDC formulations
and extracted into Excel worksheets the product, volume, and value data. We summed the
monthly data to obtain 12-mo volumes and values for the 5-y period November 2007–October
2012. The database was additionally searched using the individual drug names of NSAIDs, oral
anti-diabetic drugs, anti-depressants, benzodiazepines, and anti-psychotics. This ensured that
relevant FDCs were not overlooked; for example, alprazolam + propranolol was categorised in
the database as a cardiac formulation, and naproxen + sumatriptan as a CNS therapy in the
anti-migraine group. Searches were conducted in duplicate, with discrepancies resolved by re-
searching and agreement.
Results
FDC Formulations: CDSCO Approvals and Formulations Marketed and
Approved in India, the UK, and the US
CDSCO approvals for FDC formulations. Between 1961 and 2013, the CDSCO approved
some 1,125 oral FDC formulations including 67 NSAID FCD formulations (of which 52 were
original formulations and 15 were variants where, for example, the dose of one component was
changed or a modified release dose form used), 41 metformin FDC formulations (21 original,
20 variants), nine original benzodiazepine/anti-depressant formulations, and five original anti-
psychotic drug formulations (Table 1). While some older formulations had become obsolete by
2011–2012 (e.g., indomethacin + dexamethasone, approved November 1971; trifluoperazine
+ analgin + ergotamine + caffeine, approved March 1976), 60 of these 87 approved original for-
mulations were available on the market in 2011–2012.
An Examination of FDCs in Four Therapeutic Areas
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In each therapeutic area, more new(original) formulations were launched on the market
after 1 May 2002 than before (Table 1). Overall, the proportions of formulations with CDSCO
approval after 1 May 2002 were unchanged compared with before 1 May 2002. The propor-
tions of formulations with CDSCO approval increased for NSAID FDCs (26% to 28%) and
anti-psychotic FDCs (0% to 38%) and decreased for metformin FDCs (100% to 75%) and anti-
depressant/benzodiazepine FDCs (20% to 18%) (Table 1).
With the exception of the NSAID FDC aspirin + caffeine, none of the FDCs on the market
in the therapeutic areas examined were included in the Indian Pharmacopoeia [22].
FDC formulations marketed and approved in India, the UK, and the US. There were
124 NSAID formulations on the market in India (2011–2012), of which 34 (27%) were ap-
proved in India, six in the UK, and ten in the US (Table 1); 25 metformin FDC formulations in
India, of which 20 were approved in India (80%), eight in the UK, and ten in the US; 16 anti-
depressant/benzodiazepine FDC formulations in India, of which three (19%) were approved in
India, none in the UK, and one in the US; and ten anti-psychotic FDC formulations in India, of
which three (30%) were approved in India, none in the UK, and one in the US. All the formula-
tions available in the UK and US in each therapeutic area were approved by the respective regu-
lators. Formulations for which there was no record of CDSCO approval continued to be
marketed after 1 May 2002; less than half of NSAID, anti-depressant/benzodiazepine, and anti-
psychotic FDC formulations and 75% of metformin FDC formulations marketed after that
date had records of CDSCO approval.
Of NSAID FDC formulations, 2/6 approved in the UK and 7/10 approved in the US were
not found in India (UK: ibuprofen + phenylephrine, ketoprofen + omeprazole; US: ibuprofen
+ diphenhydramine, ibuprofen + famotidine, ibuprofen + hydrocodone, ibuprofen + oxyco-
done, ibuprofen + phenylephrine, naproxen + esomeprazole, naproxen + pseudoephedrine).
Of metformin FDC formulations, two were recently approved in the UK and the US and were
not found in India (metformin + alogliptin [2013], metformin + canagliflozin [2014]). One
anti-depressant/benzodiazepine FDC approved in the US (amitriptyline + chlordiazepoxide)
was also available in India but was not included in the CDSCO’s list of approved FDCs. One
anti-psychotic FDC approved in the US (amitriptyline + perphenazine) was unavailable in
both the UK and India.
FDC Products Arising from Unapproved Formulations
Individual formulations gave rise to multiple branded products. On average, the ratio of formu-
lations to products was around 1:20 (Table 1), but several formulations had many more prod-
ucts (Tables 2–4 and S2). The 124 NSAID FDC formulations gave rise to 2,739 products
(excluding “other”), 25 metformin formulations to 536 products, 16 anti-depressant/benzodi-
azepine formulations to 301 products, and ten anti-psychotic formulations to 211 products.
Overall, unapproved formulations gave rise to substantial proportions of branded products for
all groups except metformin FDCs: 43% of NSAID FDC products, 76% of anti-depressant/ben-
zodiazepine FDC products, 78% of anti-psychotic FDC products, and 2% of metformin FDC
products (Table 1 and Fig 1)
The 19 NSAID formulations launched on the market before 1 May 2002 gave rise to 1,895
NSAID branded products, of which 31% (n = 583) were from unapproved formulations. Of
844 products arising from the 105 formulations marketed after 1 May 2002, 69% (n = 582)
were from unapproved formulations (Table 1). Among metformin FDCs, no products mar-
keted before 1 May 2002 were from unapproved formulations, compared with 9% (n = 28)
after 1 May 2002. For antidepressant/benzodiazepine FDCs and anti-psychotic FDCs, 87% and
An Examination of FDCs in Four Therapeutic Areas
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Table 2. Metformin FDC formulations marketed in India.
Formulations of
FDCs with
Metformin
FDC Sales
Volume Nov
2011–Oct
2012 in
Millions of
Tablets/
Capsules
Percent of
FDC Total
Volume
FDC Value Nov
2011–Oct 2012
in Millions of
Rupees
(Millions of US
Dollars)
Percent
of FDC
Total
Value
Number of
Branded
Products (with
Sales in 2011–
2012)
Market
Launch
Date for
First FDC
Product
Date of CDSCO
First Approval
of Original
Formulation
Approved
in UK/US
Individual
formulations
Glimepiride 1,588.3 34.87% 7,436.92 36.97% 137 (110) Sep 2002 Nov 2002 N/N
Glimepiride,
pioglitazone
772.8 16.97% 4,112.06 20.44% 68 (63) Dec 2003 Dec 2005 N/N
Glipizide 683.8 15.01% 563.98 2.80% 25 (15) Nov 1998 Mar 1998 N/Y
Glibenclamide* 487.5 10.70% 977.86 4.86% 33 (24) Aug 2001 Nov 1995 N/N
Gliclazide 438.1 9.62% 2,007.70 9.98% 102 (69) Nov 1999 Apr 2005 N/N
Pioglitazone 154.4 3.39% 713.77 3.55% 61 (49) Feb 2001 Feb 2002 Y/Y
Glibenclamide,
pioglitazone
112.1 2.46% 480.80 2.39% 14 (14) Mar 2007 Feb 2009 N/N
Voglibose 104.0 2.28% 586.45 2.92% 37 (37) Apr 2007 Jul 2007 N/N
Vildagliptin 99.5 2.18% 1,512.11 7.52% 3 (3) May 2009 Jul 2008 Y/N
Sitagliptin 56.9 1.25% 1,336.70 6.65% 2 (2) Apr 2008 Apr 2008 Y/Y
Gliclazide,
pioglitazone
21.6 0.47% 118.61 0.59% 4 (4) Nov 2007 May 2010 N/N
Voglibose,
glimepiride
20.3 0.45% 167.28 0.83% 6 (6) Jul 2011 Not listed N/N
Acarbose 8.6 0.19% 53.56 0.27% 2 (2) Apr 2008 Feb 2009 N/N
Repaglinide 2.2 0.05% 17.38 0.09% 1 (1) Sep 2010 Aug 2010 N/Y
Miglitol 2.1 0.05% 17.26 0.09% 2 (2) Oct 2007 Oct 2007 N/N
Gliclazide,
rosiglitazone
1.9 0.00% 0.001 0.00% 2 (1) Apr 2007 Aug 2006 N/N
Glimepiride,
atorvastatin
1.8 0.04% 11.0 0.05% 8 (4) Apr 2007 Dec 2009 N/N
Rosiglitazone** 1.5 0.00% 0.68 0.00% 11 (8) Jan 2001 Oct 2001 N/Y
Glibenclamide,
rosiglitazone
0.2 0.00% 0.79 0.00% 5 (4) May 2004 Aug 2006 N/N
Pioglitazone,
picolinic acid
0.1 0.00% 0.34 0.00% 2 (1) Jun 2003 Not listed N/N
Glimepiride,
rosiglitazone
0.076 0.00% 0.31 0.00% 6 (3) Jul 2006 Nov 2002 N/N
Nateglinide 0.057 0.00% 0.24 0.00% 1 (1) Jun 2006 Aug 2004 N/N
Glimepiride,
ramipril
0.002 0.00% 0.005 0.00% 2 (1) Apr 2007 Not listed N/N
Glimepiride,
atorvastatin,
ramipril~
0 0.00% 0 0.00% 1 (0) Apr 2007 Not listed N/N
Total 4,557.8 100.00% 20,115.9
(US$323.0)
100.00% 536
(424, 79%)
Marketed before
1 May 2002
1,765.3 38.7% of total 4,264.0
(US$66.8)
21.2% of
total
232
(43% of total)
CDSCO-
approved
1,765.3 4,264.0
Marketed after 1
May 2002
2,792.6 61.3% 15,851.9
(US$25.6)
78.8% 304 (57%)
(Continued)
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100%, respectively, of products marketed before 1 May 2002 were from unapproved formula-
tions, compared with 62% and 57% after 1 May 2002 (Table 1).
FDC Sales: Sales Trends for 2007–2012 and Sales Volumes (2011–
2012) Arising from Unapproved Formulations
The total oral drug market in each therapeutic area was composed of FDCs and SDFs
(Table 1). Sales volumes of NSAIDs and metformin/anti-diabetes drugs were substantial com-
pared with anti-depressants/benzodiazepines and anti-psychotics. During the 5 y examined,
FDCs comprised increasing annual proportions of total sales volumes (Fig 2), and by 2011–
2012 they accounted for over half of all NSAIDs and oral anti-diabetic drugs sold, one-third of
anti-psychotic drugs, and almost one-fifth of anti-depressants/benzodiazepines (Table 1).
Overall, across the four therapeutic areas, approved and unapproved formulations contrib-
uted varying proportions of FDC sales volumes: almost all metformin FDC sales were from
CDSCO-approved formulations, but formulations unapproved by the CDSCO accounted for
over two-thirds of anti-depressant/benzodiazepine FDC sales (69%), almost half of anti-psy-
chotic FDCs (43%), and more than a quarter of NSAID FDCs (28%) (Table 1). Sales values fol-
lowed generally similar patterns. Fig 1 summarises the proportions of formulations and
products on the market and sales volumes and value in 2011–2012 arising in each therapeutic
area from unapproved formulations.
Formulations marketed before 1 May 2002 accounted for most of the NSAID FDC sales vol-
ume (5,397.3 million tablets/capsules); 14% of this volume arose from unapproved formula-
tions. In contrast, of the sales volume arising from formulations marketed after 1 May 2002
(1,743.8 million tablets/capsules), 74% was from unapproved formulations. Five metformin
FDC formulations marketed after 2002 had no record of CDSCO approval, but their
Table 2. (Continued)
Formulations of
FDCs with
Metformin
FDC Sales
Volume Nov
2011–Oct
2012 in
Millions of
Tablets/
Capsules
Percent of
FDC Total
Volume
FDC Value Nov
2011–Oct 2012
in Millions of
Rupees
(Millions of US
Dollars)
Percent
of FDC
Total
Value
Number of
Branded
Products (with
Sales in 2011–
2012)
Market
Launch
Date for
First FDC
Product
Date of CDSCO
First Approval
of Original
Formulation
Approved
in UK/US
Individual
formulations
CDSCO-
approved
2,772.1 15,684.2
Unapproved 20.4 167.6
CDSCO ever-
approved
formulations
4,537.4 99.6% 19,948.2
(US$321.9)
99.2%
Sales volume (millions of tablets/capsules) and value (millions of Rupees [US dollars]) in amounts and as proportions of total volume and value; numbers
of branded products of each formulation on the market by October 2012 (numbers of products with sales recorded in 2011–2012); market launch date for
the ﬁrst FDC product; CDSCO ﬁrst approval date for the original formulation; approval of the FDC in UK and/or US (N = not approved; Y = approved).
FDC formulations on the market with and without a record of CDSCO approval are termed respectively “approved” and “unapproved”. Data sources:
PharmaTrac; CDSCO-published list of FDC approvals 1961–February 2013. Conversion rate: INR 1 INR = US$0.016. Small differences in totals arise
from rounding.
*Glibenclamide is known as glyburide in the US.
**Rosiglitazone approval withdrawn in India 2005.
~Sales recorded in preceding years.
doi:10.1371/journal.pmed.1001826.t002
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Table 3. Anti-depressant/benzodiazepine FDC formulations marketed in India.
Formulations of Anti-
Depressant/
Benzodiazepine FDCs
FDC Sales Volume
Nov 2011–Oct
2012 in Millions of
Tablets/Capsules
Percent of
FDC Total
Volume
FDC Value Nov
2011–Oct 2012 in
Millions of Rupees
Percent of
FDC Total
Value
Number of
Branded
Products (with
Sales in 2011–
2012)
Market
Launch Date
for First FDC
Product
Date of CDSCO
Approval of
Original
Formulation
Individual formulations
Amitriptyline
+ chlordiazepoxide
229.7 35.97% 399.58 19.87% 62 (45) May 2001 Not listed
Escitalopram
+ clonazepam
168.0 26.31% 1,005.95 50.02% 48 (43) Mar 2005 Aug 2004
Imipramine
+ diazepam
67.7 10.60% 71.27 3.54% 36 (24) Nov 2001 Not listed
Alprazolam
+ propranolol
54.2 8.49% 124.78 6.20% 44 (34) Jul 2001 Not listed
Alprazolam
+ melatonin
28.8 4.51% 49.88 2.48% 6 (3) Dec 2000 Not listed
Alprazolam
+ sertraline
24.6 3.85% 87.35 4.34% 23 (11) Apr 2002 Sep 2006
Etizolam
+ escitalopram
18.5 2.90% 98.29 4.89% 6 (6) Oct 2008 Not listed
Diazepam
+ propranolol
11.3 1.78% 23.44 1.17% 16 (12) Apr 2007 Not listed
Alprazolam
+ ﬂuoxetine
9.9 1.54% 30.17 1.50% 20 (9) Nov 2002 Not listed
Paroxetine
+ clonazepam
5.9 0.93% 52.0 2.59% 1 (1) Aug 2011 Aug 2010
Duloxetine
+ mecobalamin
5.1 0.80% 29.94 1.49% 15 (12) Jul 2006 Not listed
Clonazepam
+ propranolol
2.8 0.44% 7.88 0.39% 7 (7) Mar 2009 Not listed
Desvenlafaxine
+ clonazepam
1.8 0.28% 17.13 0.85% 1 (1) Nov 2011 Not listed
Imipramine
+ chlordiazepoxide
0.4 0.06% 0.58 0.03% 3 (2) Apr 2007 Not listed
Alprazolam
+ imipramine
0.4 0.06% 0.42 0.02% 5 (1) Apr 2007 Not listed
Alprazolam
+ paracetamol*
0 0.00% 0 0.00% 2 (0) Mar 2003 Not listed
Other combinations 9.5 1.37% 12.53 0.49% 6 (2) Excluded Excluded
Total 638.5 99.89% 2,011.18
(US$32.54 million)
99.87% 301
(213, 71%)
Marketed before 1 May
2002 (excluding “other
combinations”)
405.0 63.4% of
total
732.9 36.4% of
total
CDSCO-approved 24.6 3.9% 87.4 4.3%
Unapproved 380.4 59.6% 645.5 32.0%
Marketed after 1 May
2002 (excluding “other
combinations”)
224.1 35.1% 1,265.8 63.0%
CDSCO-approved 173.9 27.2% 1,058.0 52.6%
Unapproved 50.2 7.9% 207.9 10.3%
CDSCO ever-approved
formulations
198.5 31.1% 1,145.3 56.9%
Unapproved 430.6 67.4% 853.4 42.4%
Other combinations 9.5 1.4% 12.5 0.5%
(Continued)
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contribution to overall sales volume was low (0.4%). For anti-depressant/benzodiazepine and
anti-psychotic FDCs, sales arising from formulations marketed before 1 May 2002 were com-
prised almost entirely of products arising from unapproved formulations; of sales arising from
formulations marketed after 1 May 2002, however, 25%–29% were from
unapproved formulations.
Formulation Composition, CDSCO Approval, Sales Volumes, and
Numbers of Branded Products Marketed
NSAIDs. Four CDSCO-approved formulations, each comprising a NSAID and paraceta-
mol, accounted for 61% of total FDC sales volumes: ibuprofen (2,400 million tablets/capsules),
diclofenac (797 million), aceclofenac (715 million), and nimesulide (558 million). Together,
the four formulations gave rise to hundreds of branded products, of which some were new to
the market during 2007–2012 and had rising sales and some were older and had declining sales
(ibuprofen + paracetamol, 158 products; diclofenac + paracetamol, 298; aceclofenac + paraceta-
mol, 327; nimesulide + paracetamol, 292) (S2 Table).
The remaining 30 CDSCO-approved formulations comprised 8% of sales volumes. Most
frequently, these were NSAID combinations with muscle relaxants (chlorzoxazone, dicyclo-
mine, drotaverine, thiocolchicoside, tizanidine, tolperisone) or proteolytic enzymes (serratio-
peptidase, trypsin-chymotrypsin). There were also combinations with misoprostol, tranexamic
acid, and sumatriptan (S2 Table). The marketing date preceded the CDSCO approval date for
23/34 approved formulations.
Ninety unapproved formulations accounted for 28% of sales volumes, and unspecified
“other” formulations for 2.6%. The top-selling unapproved formulations were mefenamic acid
+ dicyclomine, 4.7% of sales; aceclofenac + paracetamol + serratiopeptidase, 4.4%; ibuprofen
+ paracetamol + caffeine, 2%; and diclofenac + paracetamol + chlorzoxazone, 2%. Other unap-
proved formulations included FDCs of NSAIDs with paracetamol plus a muscle relaxant, tra-
madol, dextropropoxyphene, anti-ulcer agent, anti-histamine, caffeine, another NSAID, or
sumatriptan (S2 Table).
Metformin. CDSCO-approved formulations accounted for almost all sales by volume in
2011–2012 (total sales 4,558 million tablets/capsules) (Table 2). The marketing date preceded
the CDSCO approval date for 11/20 approved formulations. The most popular FDCs were dual
Table 3. (Continued)
Formulations of Anti-
Depressant/
Benzodiazepine FDCs
FDC Sales Volume
Nov 2011–Oct
2012 in Millions of
Tablets/Capsules
Percent of
FDC Total
Volume
FDC Value Nov
2011–Oct 2012 in
Millions of Rupees
Percent of
FDC Total
Value
Number of
Branded
Products (with
Sales in 2011–
2012)
Market
Launch Date
for First FDC
Product
Date of CDSCO
Approval of
Original
Formulation
Individual formulations
Total 638.6 100% 2,011.2 99.8%
Sales volume (millions of tablets/capsules) and value (millions of rupees [US dollars]) in amounts and as proportions of total volume and value in each
therapeutic area (2011–2012); numbers of branded products of each FDC formulation on the market by October 2012 (numbers of products with sales
recorded in 2011–2012); market launch date for the ﬁrst FDC product; CDSCO ﬁrst approval date for the original formulation. Note: To avoid double-
counting, FDCs containing an anti-psychotic and an anti-depressant were counted only in the anti-psychotic FDC category. FDC formulations on the
market with and without a record of CDSCO approval are termed respectively “approved” and “unapproved”. Data sources: PharmaTrac; CDSCO-
published list of FDC approvals 1961–February 2013. Conversion rate: INR 1 = US$0.016. Small differences in totals arise from rounding.
* Sales recorded in 2007 through 2010.
doi:10.1371/journal.pmed.1001826.t003
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combinations with sulfonylureas (glimepiride, glipizide, gliclazide, glibenclamide) and a triple
combination with glimepiride and pioglitazone (Table 2). These formulations gave rise to 536
branded products, most (n = 424, 79%) with sales recorded in 2011–2012. Metformin + glime-
piride had 137 different products; metformin + gliclazide, 102; metformin + glimepiride + pio-
glitazone, 68; and metformin + pioglitazone, 61.
Table 4. Anti-psychotic FDC formulations marketed in India.
Formulations of Anti-
Psychotic FDCs
FDC Sales Volume
Nov 2011–Oct 2012
in Millions of
Tablets/Capsules
Percent of
FDC Total
Volume
FDC Value Nov
2011–Oct 2012
in Millions of
Rupees
Percent of
FDC Total
Value
Number of
Branded
Products (with
Sales in 2011–
2012)
Market
Launch Date
for First FDC
Product
Date of CDSCO
Approval of
Original
Formulation
Individual formulations
Flupenthixol
+ melitracen
221.9 52.92% 875.30 68.55% 25 (24) Jan 2005 Oct 1998
Risperidone
+ trihexyphenidyl
72.8 17.36% 236.57 18.53% 50 (42) Apr 2001 Not listed
Triﬂuoperazine
+ trihexyphenidyl
71.1 16.96% 58.60 4.59% 1 (1) Aug 2002 Not listed
Chlorpromazine
+ trihexyphenidyl
+ triﬂuoperazine
18.8 4.49% 9.46 0.74% 27 (18) Sep 2004 Not listed
Olanzapine
+ ﬂuoxetine
15.2 3.62% 73.34 5.74% 14 (7) Jul 2003 Feb 2003
Triﬂuoperazine
+ chlordiazepoxide
14.0 3.35% 18.46 1.45% 52 (41) Oct 2001 Not listed
Haloperidol
+ trihexyphenidyl
2.7 0.64% 2.00 0.16% 13 (9) May 2004 Not listed
Chlorpromazine
+ trihexyphenidyl
2.5 0.60% 2.70 0.21% 20 (9) Jul 2002 Not listed
Chlordiazepoxide
+ triﬂuoperazine
+ trihexyphenidyl
0.2 0.06% 0.22 0.02% 8 (3) Dec 2002 May 1979
Trihexyphenidyl
+ thioridazine
0.04 0.01% 0.16 0.01% 1 (1) Apr 2007 Not listed
Total 419.3 100% 1,276.8
(US$20.7 million)
100% 211
(154, 73%)
Marketed before 1 May
2002
86.8 20.7% of
total
255.0 20.0% of
total
CDSCO-approved 0 0.0% 0.0 0.0%
Unapproved 86.8 20.7% 255.0 20.0%
Marketed after 1 May
2002
332.5 79.3% 1,021.8 80.0%
CDSCO-approved 237.3 56.6% 948.9 74.3%
Unapproved 95.1 22.7% 72.9 5.7%
CDSCO ever-approved
formulations
237.3 56.6% 948.8 74.3%
Unapproved 181.9 43.4% 328.0 25.7%
Total 419.3 100% 1,276.8 100%
Sales volume (millions of tablets/capsules) and value (millions of rupees [US dollars]) in amounts and as proportions of total volume and value in each
therapeutic area (2011–2012); numbers of branded products of each FDC formulation on the market by October 2012 (numbers of products with sales
recorded in 2011–2012); market launch date for the ﬁrst FDC product; CDSCO ﬁrst approval date for the original formulation. Note: To avoid double-
counting, FDCs containing an anti-psychotic and an anti-depressant were counted only in the anti-psychotic FDC category. FDC formulations on the
market with and without a record of CDSCO approval are termed respectively “approved” and “unapproved”. Data sources: PharmaTrac; CDSCO-
published list of FDC approvals 1961–February 2013. Conversion rate: INR 1 = US$0.016. Small differences in totals arise from rounding.
doi:10.1371/journal.pmed.1001826.t004
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Anti-depressants/benzodiazepines. Three CDSCO-approved formulations combining a
selective serotonin reuptake inhibitor (SSRI) with a benzodiazepine comprised 31.1% of FDC
sales volumes (total sales 638.5 million tablets/capsules) in 2011–2012 (escitalopram + clonaze-
pam, 26.3%; sertraline + alprazolam, 3.9%; paroxetine + clonazepam, 0.9%) (Table 3). The
marketing date preceded the CDSCO approval date for 1/3 approved formulations (sertraline
+ alprazolam). Of 13 formulations unapproved by the CDSCO, seven were FDCs of two cen-
trally acting drugs and three were benzodiazepine + propranolol FDCs (Table 3). Benzodiaze-
pine with tricyclic antidepressant combinations accounted for 47.3% of sales. Among the most
popular FDCs, dozens of branded products were available, most with sales recorded in 2011–
2012 (Table 3).
Anti-psychotics. Of ten formulations on the market, three accounted for 56.6% (237.3
million tablets/capsules) of anti-psychotic sales in 2011–2012 (total sales 419.3 million tablets/
capsules) (olanzapine + fluoxetine; chlordiazepoxide + trifluoperazine + trihexyphenidyl; flu-
penthixol + melitracen) (Table 4). CDSCO approval preceded the marketing date in all cases.
The most popular was flupenthixol + melitracen (221.9 million tablets/capsules, 53% of sales
volume). Seven formulations included trihexyphenidyl (benzhexol).
FDC Formulations with State Licenses but Not Approved by the CDSCO
The list of 294 FDCs with state licenses but unapproved by the CDSCO included 72 NSAID
FDC formulations, of which 33 were on the market; 15 anti-depressant/benzodiazepine FDC
Fig 1. Proportions of formulations on the market, products on the market, sales volume, and sales value in each therapeutic area arising from
formulations unapproved by the CDSCO. *Excludes “other” formulations.
doi:10.1371/journal.pmed.1001826.g001
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formulations, with five on the market; and one metformin formulation not marketed [14]. No
anti-psychotic formulations were listed.
FDCs Including Drugs Banned, Restricted, or Never Approved
Internationally
Multiple formulations, most without CDSCO approval, included drugs banned, restricted, or
never approved internationally owing to adverse effects (Table 5) [23–29]. Sales volumes were
generally high. None of these drugs had MHRA (UK) or FDA (US) approval.
Many NSAID FDC formulations available in India (both approved and unapproved) in-
cluded muscle relaxants or proteolytic enzymes, of which several were approved as SDFs in the
UK and/or US but none were components of NSAID FDCs in either country (Table 6). FDCs
including two NSAIDs (diclofenac + nimesulide, mefenamic acid + ibuprofen) were not ap-
proved in the UK or the US.
Discussion
In quantifying the use of FDCs in four different therapeutic areas and determining the relative
contributions of CDSCO-approved and-unapproved FDCs, this study confirms the concerns
of the 59th Report about FDC regulation in India. In three of the four areas examined, there
were more unapproved formulations on the market than approved formulations. In turn these
had given rise to hundreds—and in the case of NSAIDs, thousands—of branded products.
Many millions of doses were sold of FDCs that included drugs restricted, banned, or never
Fig 2. FDCs as proportions of total annual oral drug sales volumes in each therapeutic area, November 2007–October 2012.Metformin FDCs are
expressed as a percent of total oral diabetes drugs. Numerator and denominator data are included in S3 Table.
doi:10.1371/journal.pmed.1001826.g002
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approved in other countries owing to their association with serious adverse events
including fatality.
Multiple formulations of the FDCs studied were marketed without any record of CDSCO
approval, supporting the concern that “many FDCs in the market have not been tested for effi-
cacy and safety” (Section 9.2 of [6]). This occurred despite the legal need since 1961 for a new
drug to have been approved before manufacture, including an FDC meeting the applicable
Table 6. Muscle relaxants and proteolytic enzymes included in NSAID FDC formulations marketed in India.
NSAID FDC Component MHRA Market
Authorisation
as SDF, UK [17]
FDA Approval as
SDF, US [18]
Clinical Action Percent NSAID FDC Sales
in 2011–2012 in India
Including the Drug (Millions
of Tablets/Capsules)
Chlorzoxazone N Y Muscle relaxant 4.09% (300)
Dicyclomine (Dicycloverine) Y Y Muscle relaxant 5.68% (4,165)
Drotaverine N N Muscle relaxant 1.25% (91.9)
Methocarbamol Y Y Muscle relaxant 0.07% (4.8)
Serratiopeptidase N N Proteolytic enzyme 9.73% (713.5)
Tizanidine Y Y Muscle relaxant 1.14% (83.7)
Tolperisone N N Muscle relaxant 0.02% (1.6)
Trypsin-chymotrypsin N N Proteolytic enzyme 0.56% (41.2)
Muscle relaxants and proteolytic enzymes included in NSAID FDC formulations, their MHRA and FDA approval status SDFs, and the proportions of
NSAID FDCs sales volumes in India (2011–2012) that included the drugs. N, no; Y, yes.
doi:10.1371/journal.pmed.1001826.t006
Table 5. Drugs withdrawn or restricted internationally that were included in FDC formulationsmarketed in India.
Drug Name (FDC
Therapeutic Area That
Included the Drug)
Withdrawn/Restricted
Status Internationally
Reason Number of FDC
Formulations
Available in India
Number of
Formulations
Approved by the
CDSCO
FDC Percent Sales in
2011–2012 in India
Including the Drug
(Millions of Tablets/
Capsules)
Nimesulide (NSAIDs) Banned in multiple
countries; EMA
restriction 2007, 2011
[23]
Liver toxicity 15 1 NSAIDs 10.1% (723)
Thiocolchicoside (NSAIDs) EMA restriction 2013
[24]
Aneuploidy 6 5 NSAIDs 2.2% (157)
Dextropropoxyphene
(NSAIDs)
Banned in multiple
countries; withdrawn in
EU [25], also Australia,
US
Fatality in
overdose
4 0 NSAIDs 0.3% (21)
Metamizole (Analgin)
(NSAIDs)
Banned in multiple
countries [26]
Agranulocytosis 1 (with nimesulide) Withdrawn 2013 NSAIDs 0.004% (0.27)
Melitracen (anti-psychotics) Approved for export only
in Denmark [27,28];
manufacturer Lundbeck
Multiple CNS
effects
1 (with ﬂupenthixol) Withdrawn 2013, re-
listed, withdrawn
2014
Anti-psychotics 52.9%
(222)
Thioridazine (anti-
psychotics)
Withdrawn worldwide
2005 [29]
Cardiac
arrhythmias;
sudden death
1 0 Anti-psychotics 0.008%
(0.04)
Drugs withdrawn or restricted internationally but included in FDCs in India, reasons for withdrawal, numbers of FDC formulations available in India,
CDSCO approval status, and the proportions (volume) of FDCs sales in India (2011–2012) that included the drugs.
EMA, European Medicines Agency; EU, European Union.
doi:10.1371/journal.pmed.1001826.t005
An Examination of FDCs in Four Therapeutic Areas
PLOSMedicine | DOI:10.1371/journal.pmed.1001826 May 12, 2015 18 / 28
legal test (see Box 1). Unexplained “ambiguity” before 1 May 2002 regarding the licensing pow-
ers of state drug authorities is noted in the 59th Report as a possible contributor (Section 9.2 of
[6]). In our analysis of the data in four therapeutic areas, we found no notable differences in
the overall proportion of centrally approved formulations after 1 May 2002 compared with be-
fore. In our detailed analysis of the national rules (S1 Text), we found no ambiguity relating to
the question of whether an FDC needed central approval prior to manufacture. Clearly, howev-
er, the legal test until 1988 needed to be interpreted in order to determine its application to
FDCs, and practice appears to have varied, as presumably approval was sought for some FDCs
but not for others. Numerous FDCs were marketed before the CDSCO approval date, suggest-
ing that in some cases state licenses permitting manufacturing and sale were obtained first and
approval sought retrospectively. However, state drug authority records to confirm this
were unavailable.
NSAIDs are among the most widely used drugs internationally. Almost 12 billion NSAID
tablets/capsules were sold in India in 2011–2012; NSAID FDCs comprised almost two-thirds
of these, of which 28% were unapproved formulations. Over 12% of NSAID FDC sales volumes
included drugs that have been withdrawn from international markets or have had their use re-
stricted, for example, dextropropoxyphene, metamizole, melitracen, nimesulide, and thiocol-
chicoside, owing to risks including death in overdose, liver failure, and genetic effects [23–29].
FDCs including two NSAIDs are highly undesirable due to associated gastrointestinal risks
[12]. In contrast to NSAIDs, most metformin FDC formulations had CDSCO approval and ac-
counted for practically all FDCs used and over half of total oral anti-diabetic drug sales vol-
umes. Among both groups of CNS drugs examined, unapproved formulations comprised
substantial FDC sales volumes: 69% of antidepressant/benzodiazepine FDCs and 43% of anti-
psychotic FDCs. Sales volumes of these FDCs were lower than those of NSAID and metformin
FDCs, but the combinations were commonly hazardous. Indeed, some anti-psychotic FDCs
were potentially lethal. For example, the combination chlorpromazine + trifluoperazine + tri-
hexyphenidyl contains two phenothiazine anti-psychotics independently associated with major
CNS toxicity and with cardiotoxicity including sudden death, risks also associated with FDCs
containing thioridazine [10,11,29]. Tricyclic antidepressants, benzodiazepines, and antipsy-
chotic medicines are independently associated with increased risk of falls, especially among
older patients [30]. Nevertheless, FDCs comprising these sedating classes in single formula-
tions were sold in considerable volumes.
Since 2001, the CDSCO is obliged to be satisfied as to the safety and effectiveness of prod-
ucts approved. The grounds for approval are not published, but the regulator acknowledges
having approved some new drugs without clinical data (Section 7 of [6]) [31,32]. Many formu-
lations being sold without approval contravene FDC development guidance on basic pharma-
cological parameters [8,33]. Pharmacovigilance in India is at an early stage and adverse event
reporting rates are very low, so the absence of adverse event reports offers no reassurance of
the safety of such formulations (Sections 8 and 12 of [6]) [34–36]. Overall, among the four
therapeutic areas examined, most of the FDC formulations available in India were unavailable
in either the UK or the US.
The study has limitations. We relied on publicly available records for central approvals and
commercial sales records to determine the formulations marketed, the market launch dates,
and the sales volumes. These sources were not compiled in order to support research, and they
cannot be independently verified. Nevertheless, they are nationwide datasets that permit infor-
mative examination of data relevant to complaints about regulation and use in India of FDCs.
The sales data reflect mainly private out-of-pocket prescription spending. Sales through hospi-
tals and dispensing doctors may include government-subsidised drugs, but we could not con-
firm this. In comparing the numbers of formulations on the market in India in each
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therapeutic area with those in the UK and US, it is possible that some formulations listed in
PharmaTrac as “other” were overlooked and not identified by us owing to small volumes sold.
We cross-checked FDC formulations approved in the UK and US but not found in Pharma-
Trac with the MIMS India listings and found two additional metformin FDCs available in
India (with linagliptin and saxagliptin) [37]. We found no additional NSAID or psychotropic
FDCs listed in MIMS India. Other than the list of 294 banned FDCs, we did not have informa-
tion on manufacturing/distribution licences granted by state drug authorities. The list of
banned FDCs, however, was consistent with the 59th Report’s claim that some FDCs were li-
censed by states without prior CDSCO approval. Notwithstanding the limitations of the sales
data and the absence of systematic central regulatory and state licensing records, this study
substantiates the complaints of the 59th Report in demonstrating that regulatory problems in
India extend well beyond widely publicised concerns about manufacturing standards.
Factors Potentially Contributing to the Large Numbers of FDCs
In the four therapeutic areas examined, most of the FDC formulations available in India were
unavailable in the UK and US. FDCs were sold in large volumes. They dominated oral NSAID
and diabetes drug sales and comprised substantial sales proportions in the CNS areas. In con-
trast, National Health Service data for publicly subsidised prescribed medicines that were dis-
pensed in England show that metformin FDCs accounted for<5% of oral diabetes drug use in
2012 [38]. There was no FDC dispensing recorded in the other therapeutic areas [38].
Problematic production and use in India of FDCs will not be rectified without addressing
the contributing causes. A commonly cited driver, though not discussed in the 59th Report, is
manufacturers’ desire to avoid government price controls imposed on drugs included on the
National List of Essential Medicines of India [39]. Price control has been evaded by including
these drugs in FDC formulations [39,40] (though amendments in the 2013 National Pharma-
ceutical Pricing Policy may prevent this) [41]. However, price control could also be evaded by
manufacturing SDFs of different strength to those on the National List of Essential Medicines
of India [39], and the evasion argument does not explain why prescribers prefer FDCs. Neither
does it explain the large numbers of FDC products on the market.
Attempts been made to improve India’s drug regulatory situation following the 59th Report.
The Drugs Controller General (India) (DCG[I]) requested that states ask manufacturers to
prove the safety and efficacy of their FDCs licensed without central approval within a period of
18 mo (January 2013) [42], policy guidelines for approval of FDCs were published (June 2013)
[43], and the Chaudhury committee made recommendations on new drugs, clinical trials, and
banning of drugs (July 2013) [44]. Legislative underpinning for the 18-mo safety and efficacy
review, however, was lacking, and following industry lobbying, the DCG(I) excluded from it
FDCs licensed before 21 September 1988 (June 2014) [45]. The president of Indian Drug Man-
ufacturers’ Association subsequently made “an earnest appeal” to the Ministry of Health and
Family Welfare to “maintain status quo” for FDCs licensed by states or approved by DCG(I)
up to 30 September 2012 [46].
In our view, significant factors contributing to the large number of FDCs on the market in-
clude structural problems with provisions of the Drugs and Cosmetics Rules, 1945, stemming
partly from the aged Drugs and Cosmetics Act, 1940, and amendments to the rules (2005)
[47]. These include: the blurring over time of the initial clarity of responsibility between central
government (responsible for imported drugs) and the states (responsible for manufacture, dis-
tribution, and sale); the absence of a duty on the regulator in the Drugs and Cosmetics Act,
1940, to be satisfied of a new drug’s safety and effectiveness; the apparently random inter-
changeability of the different concepts of efficacy and effectiveness; the unclear and
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contradictory scope of the FDCs that are covered by the 1988 rules, and their inconsistency
with WHO guidelines [8]; and the downgrading in 2005 of data submission requirements [40].
The Drugs and Cosmetics (Amendment) Bill introduced in Parliament in 2013 and the pro-
posed version put out for 12 d of consultation by the Ministry of Health and Family Welfare on
31 December 2014 are not aimed at these issues [48,49].
Recommendations
First, there should be an immediate ban on sales and manufacturing of FDCs not approved by
the CDSCO. Withdrawal from the market should be staged, prioritising FDCs that include
drugs banned or unapproved internationally and potentially most likely to harm patients. Pre-
scribers need to review the needs of patients taking these FDCs, taper off the drugs, and substi-
tute appropriate alternatives prescribed as SDFs with monitoring of benefit/need. Approved
FDC formulations containing drugs that have been withdrawn or restricted by other regulators
should be reviewed with the intention of applying similar restrictions in India unless a strong
evidence base dictates otherwise. All other approved FDCs should be reviewed for continuing
approval. In all cases, the evidence and rationale for decisions need to be made freely available.
This means that the Ministry of Health and Family Welfare should exercise its statutory powers
to prohibit the import, manufacture, distribution, and sale of FDCs under Section 10A or 26A
of the Drugs and Cosmetics Act, 1945 [15], in line with any CDSCO recommendations or, in
the event of it not doing so, should explain and publish its reasoning.
Second, transparency and accountability of regulatory decisions must be improved. Com-
plete details of approvals, including the clinical evidence base, need to be made available by the
CDSCO for public scrutiny. Support needs to be provided to the CDSCO in terms of planning,
information systems, and skilled personnel in order to achieve this.
Third, the CDSCO and the state authorities should establish transparent and public proce-
dures for ensuring that notice of all new drug approvals given by the CDSCO is immediately
given to each state licensing authority, and vice versa for all manufacturing, distribution, and
sale licences granted by each state. Such notices should be published on the websites of the
CDSCO and the state licensing authorities.
Finally, following the DCG(I)’s worrying restriction of the FDC safety and efficacy review,
and the 2014 parliamentary elections, the new Parliament should monitor closely the activities
of the Ministry of Health and Family Welfare and the CDSCO. If the proposed Drugs and Cos-
metics (Amendment) Bill, 2015, reaches Parliament [49], opportunity exists for legislators to
propose amendments on safety, effectiveness, rationality, need, and, perhaps most importantly,
transparent regulation. Requiring a review of the safety and effectiveness of all currently avail-
able FDCs, not unlike the legally required review mandated by the US Congress in 1962, rather
than the administrative review that has been shown to be susceptible to industry lobbying,
makes eminent sense [50].
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Editors' Summary
Background
Patients who are prescribed several different tablets to treat a single condition or multiple
coexisting conditions often find it hard to take all their drugs correctly. For some condi-
tions, clinicians can improve medication compliance by prescribing a fixed dose combina-
tion (FDC) product, a drug formulation containing two or more active drugs combined in
a fixed ratio of doses that are usually available only in a single dosage form. FDCs, which
are sometimes called “polypills,” are particularly useful in situations where both the drug
combination and the doses needed to treat patients are standardized and stable, such as in
the management of HIV/AIDS. FDCs can also be cheaper to manufacture and easier to
distribute than single drug formulations, but they nevertheless have some disadvantages
over such formulations. For example, the risks of adverse effects can be compounded by
including multiple drugs from the same therapeutic group in a single FDC. Thus, to pre-
vent patients being given unsafe or dangerous formulations, many countries regulate the
development and marketing of FDCs.
WhyWas This Study Done?
Concerns have been expressed internationally about the regulation of medicinal drugs in
India, where thousands of FDCs are available. In response to these concerns, in 2011, an
Indian parliamentary standing committee closely examined the Indian national drug regu-
lator—the Central Drugs Standard Control Organization (CDSCO). The committee’s re-
port, released in 2012, highlighted multiple deficiencies in the approval processes of the
CDSCO, including a failure to test the efficacy and safety of many of the FDCs available in
India, but provided no systematic evidence to support its concerns about FDCs. Here, the
researchers undertake a time-trend analysis of the sales volumes of oral FDCs for pain re-
lief (analgesia; formulations of non-steroidal anti-inflammatory drugs, NSAIDs), diabetes
(metformin formulations), depression/anxiety (anti-depressant/benzodiazepine formula-
tions), and psychosis (anti-psychotic formulations) in India between 2007 and 2012. In ad-
dition, they undertake a cross-sectional examination of data from 2011–2012 to determine
the contributions to FDC product numbers and sales volumes of formulations with a
known record of CDSCO approval (referred to as “approved”) and those for which such a
record could not be found (referred to as “unapproved”).
What Did the Researchers Do and Find?
The researchers obtained information on FDC formulations approved between 1961 and
2013 in each therapeutic area from the CDSCO, and FDC sales data from 2007 to 2012
from PharmaTrac, a database of drug sales in India. Of the 175 FDC formulations mar-
keted in India in the therapeutic areas studied, only 60 (34%) were approved. Although
80% of 25 marketed metformin FDC formulations were approved, only 27% of 124
NSAID FDC formulations, 19% of 16 anti-depressant/benzodiazepine FDC formulations,
and 30% of ten anti-psychotic FDC formulations were approved. Over the five years in-
cluded in the time-trend analysis, FDCs accounted for an increasing proportion of total
sales volumes. By 2011–2012, FDCs accounted for more than half of all NSAID and oral
anti-diabetic drug sales, and one-third and one-fifth of anti-psychotic and anti-depres-
sant/benzodiazepine sales, respectively. Moreover, in 2011–2012, the proportion of FDC
An Examination of FDCs in Four Therapeutic Areas
PLOSMedicine | DOI:10.1371/journal.pmed.1001826 May 12, 2015 26 / 28
sales volumes arising from unapproved formulations was 43% for anti-psychotics, 69% for
anti-depressants/benzodiazapines, 28% for NSAIDs, and 0.4% for metformin; formula-
tions including drugs of which use is banned or restricted internationally accounted for
13.6% and 53% of NSAID and anti-psychotic FDC sales, respectively. While “ambiguity”
in the rules prior to 2002 was advanced as a reason for some FDCs having been marketed
without a record of central approval, the researchers identified no ambiguity, and in fact,
following an amendment to the rules in May 2002 that extended the requirements on ap-
proval applicants, new FDCs continued to be marketed without a record of
central approval.
What Do These Findings Mean?
Although the accuracy of these findings is likely to be limited by the use of publicly avail-
able records of drug approvals and by the use of commercial sales records, the study’s re-
sults support concerns about the marketing and use of FDCs in India. They indicate that
large numbers of unapproved formulations are available for three of the four therapeutic
areas examined, and that sales volumes of these unapproved FDCs (including FDCs that
included internationally banned or restricted drugs) are high. The researchers make sever-
al recommendations to remedy this situation, which in their view risks harming patients.
Sale and manufacture of unapproved FDC formulations, they suggest, should be banned
immediately. Withdrawal from the market should be staged, with priority given to remov-
ing those formulations containing drugs that are banned or restricted internationally.
Manufacturers who wish to retain specific FDCs on the market should be required to sub-
mit approval applications to the CDSCO. If this recommendation is implemented, the re-
searchers note, clinicians will need to review the needs of patients taking unapproved
FDCs and provide appropriate alternatives. To ensure in the long-term the safety and ef-
fectiveness of new medicines marketed in India, as well as transparency of the approval
process, the researchers call for amendments in India’s regulatory processes and drug
laws. They also suggest that a review should be undertaken of the safety and effectiveness
of FDCs currently available in India.
Additional Information
Please access these websites via the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001826.
• Wikipedia provides information about fixed dose combination products (note that
Wikipedia is a free online encyclopedia that anyone can edit; available in several
languages)
• The US Food and Drug Administration regulates all medical drugs and devices in the
US and provides information about combination products, including FDCs
• TheWorld Health Organization provides a brief introduction to FDCs and draft
guidance for the registration of FDCs
• Information about the CDSCO, the Indian national drug regulatory body, is available;
the CDSCO website includes the approved FDC list; the Indian parliamentary standing
committee report on the CDSCO is available
• The Medicines and Healthcare Products Regulatory Agency provides information on
medicines regulation in the UK
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• The European Medicines Agency provides information on medicines regulation in
Europe
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